167 related articles for article (PubMed ID: 29573846)
1. A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).
Gollins S; Massalha S; Mullard A; Williams RM; Lloyd A; Morris J; Garcia-Alonso A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):409-417. PubMed ID: 29573846
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
Brenner B; Sarfaty M; Purim O; Kundel Y; Amit L; Abramovich A; Sadeh Gonik U; Idelevich E; Gordon N; Medalia G; Sulkes A
PLoS One; 2016; 11(7):e0157548. PubMed ID: 27390847
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Tsai JY; Iannitti D; Berkenblit A; Akerman P; Nadeem A; Rathore R; Harrington D; Roye D; Miner T; Barnett JM; Maia C; Stuart K; Safran H
Am J Clin Oncol; 2005 Aug; 28(4):329-33. PubMed ID: 16062072
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
6. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
7. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
[TBL] [Abstract][Full Text] [Related]
8. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
9. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
11. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Petrioli R; Francini E; Cherri S; Marrelli D; Rovello F; Fiaschi AI; Miano ST; Savelli V; Calomino N; Farsi M; Vernillo R; Francini G
Anticancer Drugs; 2020 Mar; 31(3):292-297. PubMed ID: 31850915
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Thuss-Patience PC; Hofheinz RD; Arnold D; Florschütz A; Daum S; Kretzschmar A; Mantovani-Löffler L; Bichev D; Breithaupt K; Kneba M; Schumacher G; Glanemann M; Schlattmann P; Reichardt P; Gahn B
Ann Oncol; 2012 Nov; 23(11):2827-2834. PubMed ID: 22734012
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
17. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
[TBL] [Abstract][Full Text] [Related]
19. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Tebbutt NC; Price TJ; Ferraro DA; Wong N; Veillard AS; Hall M; Sjoquist KM; Pavlakis N; Strickland A; Varma SC; Cooray P; Young R; Underhill C; Shannon JA; Ganju V; Gebski V
Br J Cancer; 2016 Mar; 114(5):505-9. PubMed ID: 26867157
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
